“In Vitro Diagnostics Quality Control Market is expected to reach $1.61 Billion By 2029”, says Visiongain

08 January 2020
Pharma

Visiongain’s new report the In Vitro Diagnostics Quality Control Market Report 2019-2029: Forecasts by Type (Quality Control, Quality Assurance Services, Data Management Solutions), by Application (Immunochemistry, Hematology, Clinical chemistry, Molecular Diagnostics, Coagulation, Others), by End User (Hospitals, Home Care, Others), plus analysis of leading companies operating in the global In Vitro Diagnostics Quality Control market.

The rising number of accredited clinical laboratories, increasing third-party quality control services, and the strong presence of favorable regulatory bodies to drive global In Vitro Diagnostics Quality Control market over the projected period. In 2019, the global In Vitro Diagnostics Quality Control market was valued at $1.05 billion and is expected to reach $1.61 billion by 2029 at a CAGR of 4.4%. However, the unfavorable scenario of reimbursement in the IVD industry followed by the high cost of IVD quality control services is expected to hinder market growth over the coming years.

Increasing penetration of diagnostic laboratories by virtue of rising prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, and infectious diseases. Rising prevalence of chronic diseases in developed as well as developing economies to encourage global In Vitro Diagnostics Quality Control industry over the coming years.

Strong regulatory bodies associated with the regular quality check of IVD instruments and monitoring of quality control are expected to strengthen the industry. Some prominent bodies are U.S. The Food and Drug Administration, Central Drug Standard Control Organization (CDSCO), Ministry of Health, Labor & Welfare (MHLW), Ministry of Health for South Africa, Medicines and Healthcare Products Regulatory Agency (MHRA), Health Canada, Therapeutic Goods Administration (TGA), and European Medicines Agency.

List of prominent players operating in global In Vitro Diagnostics Quality Control industry are Siemens Healthcare, Abbott Diagnostics, Inc, Bio-Rad Laboratories, Inc., Danaher Corporation, Roche Diagnostics, Sysmex Corporation, Sero AS, Thermo Fisher Scientific, Inc, Sun Diagnostics, LLC, Ortho Clinical Diagnostics, Inc., Randox Laboratories Ltd, Helena Laboratories Corporation, SeraCare Life Sciences, Inc, and Technopath Clinical Diagnostics.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Generic Drugs Market Report 2020-2030

The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

03 July 2020

Read

Visiongain publishes Clinical Workflow Solutions Market Report 2020-2030

Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

03 July 2020

Read

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

Read

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever